Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-19

A pro-thrombotic milieu and a higher risk of thrombotic events were observed in patients with CoronaVirus disease-19 (COVID-19). Accordingly, recent data suggested a beneficial role of low molecular weight heparin (LMWH), but the optimal dosage of this treatment is unknown. We evaluated the associat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Thromb Thrombolysis
Hauptverfasser: Mennuni, Marco G., Renda, Giulia, Grisafi, Leonardo, Rognoni, Andrea, Colombo, Crizia, Lio, Veronica, Foglietta, Melissa, Petrilli, Ivan, Pirisi, Mario, Spinoni, Enrico, Azzolina, Danila, Hayden, Eyal, Aimaretti, Gianluca, Avanzi, Gian Carlo, Bellan, Mattia, Cantaluppi, Vincenzo, Capponi, Andrea, Castello, Luigi M., D’Ardes, Damiano, Corte, Francesco Della, Gallina, Sabina, Krengli, Marco, Malerba, Mario, Pierdomenico, Sante D., Savoia, Paola, Zeppegno, Patrizia, Sainaghi, Pier P., Cipollone, Francesco, Patti, Giuseppe
Format: Artigo
Sprache:Inglês
Veröffentlicht: Springer US 2021
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7919624/
https://ncbi.nlm.nih.gov/pubmed/33649979
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11239-021-02401-x
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge